NEXTCURE, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
NEXTCURE, INC (NXTC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $800.00 thousand for the 6-month period ending 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-18
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $300.00K, a 57.14% decline year-over-year.
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $500.00K, a 83.33% decline year-over-year.
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $400.00K, a 55.56% decline year-over-year.
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $700.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month |
|---|---|---|---|
| 2026-06-30 | $300.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-08-18 | $800.00K S-4 · filed 2026-08-18 | |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $400.00K derived: 10-Q 9 month − S-4 6 month · filed 2025-11-05 | $1.10M derived: sum of 2 quarters · filed 2026-08-18 | $4.10M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $700.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-08-18 | $3.70M S-4 · filed 2026-08-18 | |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $3.10M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |